Killer immunoglobulin-like receptors

Current Opinion in Immunology
L Moretta, A Moretta

Abstract

Killer Ig-like receptors (KIRs) are surface inhibitory receptors specific for allelic forms of human leukocyte antigen (HLA) class I molecules, which are expressed by natural killer (NK) cells and a subset of T lymphocytes. Upon engagement with HLA class I molecules, KIRs block NK cell activation and function. Cells lacking HLA class I molecules are promptly killed by NK cells because of the predominant effect of several activating NK receptors. The NK-mediated killing of these cells might represent an important defence mechanism, antagonizing spreading of pathogens and tumours. Evidence has been accumulated that KIR-encoding genes have evolved and diversified rapidly in primates and in humans. Similar to HLA loci, KIR sequences are highly polymorphic and, moreover, KIR haplotypes greatly vary in the number of the type of genes they contain. KIR gene expression is regulated by mechanisms of DNA methylation. As recently shown, the HLA class I regulated control of NK cell function can be exploited in an allogeneic bone marrow transplantation setting to eradicate acute myeloid leukaemias.

References

Aug 1, 1994·The Journal of Experimental Medicine·V LitwinL L Lanier
Feb 1, 1996·European Journal of Immunology·C Döhring, M Colonna
Jan 1, 1996·Annual Review of Immunology·A MorettaL Moretta
Jan 16, 1998·Immunity·M UhrbergP Parham
May 23, 1998·Annual Review of Immunology·L L Lanier
Jun 8, 1999·Annual Review of Immunology·E O Long
Apr 15, 2000·Seminars in Immunology·M López-BotetT Bellón
Aug 22, 2001·Immunological Reviews·H R SmithW M Yokoyama
Aug 22, 2001·Immunological Reviews·A Cerwenka, L L Lanier
Dec 26, 2001·Nature Immunology·Alessandro MorettaLorenzo Moretta
Aug 30, 2002·Trends in Immunology·Andrea VelardiLorenzo Moretta
Oct 9, 2002·The Journal of Experimental Medicine·Salim I KhakooPeter Parham
Dec 4, 2002·Nature Reviews. Immunology·Alessandro Moretta
Jan 23, 2003·The Journal of Experimental Medicine·Huei-Wei ChanCharles T Lutz
May 2, 2003·Nature·Peter Parham
Aug 13, 2003·The Journal of Experimental Medicine·Cristina BottinoAlessandro Moretta
Oct 3, 2003·Nature Reviews. Immunology·David H Raulet
Mar 25, 2004·Nature Reviews. Immunology·Eric Vivier, Nicolas Anfossi
May 12, 2004·The Journal of Experimental Medicine·Nicolas ReymondMarc Lopez

❮ Previous
Next ❯

Citations

Apr 24, 2007·Immunogenetics·Melanie Dobromylskyj, Shirley Ellis
Apr 12, 2007·Cancer Immunology, Immunotherapy : CII·Roberta CastriconiMaria Valeria Corrias
Mar 5, 2008·Cancer Immunology, Immunotherapy : CII·Karl-Johan MalmbergHans-Gustaf Ljunggren
Mar 19, 2009·Medical Molecular Morphology·Satoshi YamagiwaTakafumi Ichida
Jun 10, 2011·Molecular Biology Reports·Ozlem Goruroglu OzturkUgur Atik
Nov 9, 2007·Immunologic Research·Benjamin Bimber, David H O'Connor
Mar 16, 2005·Current Opinion in Immunology·Loredana RuggeriAndrea Velardi
Mar 31, 2005·Trends in Immunology·Cristina BottinoAlessandro Moretta
Jan 20, 2009·Leukemia·R WillemzeUNKNOWN Eurocord-Netcord and Acute Leukaemia Working Party of the EBMT
Mar 28, 2006·Bone Marrow Transplantation·Y ChalandonUNKNOWN Swiss National Donor Registry
Oct 10, 2009·Proceedings of the National Academy of Sciences of the United States of America·Noa StanietskyOfer Mandelboim
Dec 29, 2010·Proceedings of the National Academy of Sciences of the United States of America·Andrea De MariaLorenzo Moretta
Aug 6, 2009·The Journal of Biological Chemistry·Seiko NakamuraKatsumi Maenaka
Apr 11, 2007·The Journal of Experimental Medicine·Ai MasudaToshiyuki Takai
Oct 15, 2005·Current Opinion in Oncology·Ben E de Pauw
Oct 15, 2005·Current Opinion in Oncology·Anton V M B Schattenberg, Harry Dolstra
Apr 20, 2005·Journal of Immunotherapy·Loredana RuggeriAndrea Velardi
Dec 6, 2008·Veterinary Clinical Pathology·Danielle R KeltonAnthony W Confer
Jun 12, 2009·Journal of Virology·Mostafa JarahianFrank Momburg
Jan 15, 2009·Blood·Neil C RobsonEugene Maraskovsky
May 20, 2008·BMC Evolutionary Biology·Sergey V GuselnikovAlexander V Taranin
Jan 22, 2010·Molecular Cancer·Jennifer A A GubbelsManish S Patankar
Jul 28, 2005·Journal of Inflammation·Jennifer M RyanBernard P Mahon
Nov 3, 2011·Arthritis Research & Therapy·Travis Hughes, Amr H Sawalha
Jul 1, 2008·Journal of Leukocyte Biology·Guangjin LiJörg J Goronzy
Jun 17, 2006·Clinical Chemistry and Laboratory Medicine : CCLM·Tomasz SzczepańskiJacques J M van Dongen
Dec 25, 2012·Yi chuan = Hereditas·Min-Zhong TangYi Zeng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.